Last updated: February 24, 2026
What is the Drug Associated with NDC 55150-0251?
NDC 55150-0251 corresponds to Tavneos (avacopan). Avacopan is an oral complement C5a receptor inhibitor approved by the FDA in October 2021 for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Market Overview
Indications and Approved Uses
- ANCA-associated vasculitis (AAV), including GPA (granulomatosis with polyangiitis) and MPA (microscopic polyangiitis)
- Orphan drug designation decreases competition; limited to vasculitis segment
Market Size
- The global vasculitis treatment market was valued at approximately $450 million in 2022.
- The segment that avacopan targets, rare autoimmune vasculitis, comprises an estimated 10,000 to 15,000 patients in the US.
- The prevalence of AAV is 3-5 cases per 100,000 annually (Kuk et al., 2019).
Competitive Landscape
- Prior treatments: corticosteroids, rituximab, cyclophosphamide
- Avacopan’s advantages include reduced corticosteroid dependence and targeted immune modulation
- Competitors: Rituxan (rituximab), available as intravenous infusion, approved for AAV since 2011
Sales Potential
- Projected to reach peak sales of $750 million to $1 billion globally within 5-7 years post-launch
- US market share estimates range from 20-30% of AAV treatment segment by 2030
Adoption Factors
- Physician acceptance driven by clinical trial results demonstrating reduced steroid-related adverse events
- Insurance reimbursement likely to favor the drug given its targeted mechanism and safety profile
Pricing Analysis
Current Pricing Trends for Biologics and Targeted Small Molecules
- Biologics for autoimmune diseases typically range from $50,000 to $100,000 annually
- Orphan drugs often price at the higher end due to limited patient populations and high R&D costs
Estimated Price for NDC 55150-0251 (Avacopan)
- Proposed list price: approximately $50,000 to $75,000 per year per patient
- Cost comparisons:
- Rituximab infusion: $30,000 to $40,000 per treatment cycle
- Methylprednisolone: $500 to $1,000 per course
Reimbursement Outlook
- Insurance coverage likely to mirror international standards, with initial barriers reduced due to clear clinical benefits
- Value-based pricing models may influence long-term pricing adjustments
Price Projections for Next 5 Years
| Year |
Price Range |
Notes |
Market Penetration Estimate |
| 2023 |
$50,000–$60,000 |
Launch price, initial payer negotiations |
10–15% |
| 2024 |
$48,000–$58,000 |
Slight discounts due to formulary competition |
20–25% |
| 2025 |
$45,000–$55,000 |
US market saturation increases, price stabilization |
30–40% |
| 2026 |
$45,000–$ Fifty-five thousand |
Price stabilizes as competition remains limited |
40–50% |
| 2027 |
$45,000–$55,000 |
Long-term pricing steady, potential for discounts |
50%+ |
Adjustments based on market uptake, payer negotiations, and evolving treatment guidelines are expected.
Key Market Risks
- Eligibility restrictions may limit patient access.
- Competition from emerging oral therapies for vasculitis.
- Price pressure if clinical data shows comparable efficacy with less costly therapies.
Key Takeaways
- NDC 55150-0251 corresponds to avacopan, a novel therapy for AAV, with rapid market penetration expected.
- Peak US sales could approach $1 billion, supported by its targeted mechanism and orphan disease designation.
- Pricing will likely start between $50,000 and $75,000 annually, gradually stabilizing with market dynamics.
- Reimbursement success hinges on demonstrated clinical benefit and health economic value.
- Competition and payer policies will influence long-term pricing and market share.
FAQs
Q1: How does avacopan compare to existing therapies for AAV?
It offers reduced corticosteroid use and has shown efficacy in clinical trials, with a better safety profile.
Q2: What factors influence avacopan's launch pricing?
Market exclusivity, R&D costs, comparator pricing, and negotiated rebates.
Q3: Will insurance cover avacopan?
Coverage is likely favorable due to demonstrated benefits, but success depends on negotiating formulary placement.
Q4: How long will it take to reach peak sales?
Approximately 5-7 years post-launch, contingent on market adoption and competition.
Q5: Are there regulatory or reimbursement hurdles?
While the FDA approval exists, payers may impose utilization restrictions in early adoption phases.
References
- Kuk, A. Y. C., et al. (2019). "Epidemiology of vasculitis in the United States." Autoimmunity Reviews, 18(9), 102370.
- U.S. Food and Drug Administration. (2021). FDA approves Tavneos to treat certain vasculitis diseases. [https://www.fda.gov/]
- Evaluate Pharma. (2022). Biologic drug market report.
